Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM
Main finding · Composite outcomeResult — go to the resultHazard ratio 0.65Authors' conclusion
Among patients with MASLD and T2DM, SGLT2is were associated with lower risks of major clinical events compared to DPP4is, supporting their potential therapeutic role pending confirmation in randomized trials.
Study context
- Population
- Adults with MASLD and T2D initiating SGLT2i or DPP-4i between January 1, 2013, and February 28, 2025matched cohort
- Participants
- 10,232 vs 10,232
- Exposure
- SGLT2i vs DPP-4i
- SGLT2isn = 10,232
- DPP4isn = 10,232reference
- Outcome
- Composite of:
- All-cause mortality
- MACE
- Kidney events (MAKE)
- Liver outcomes (MALO)
- Follow-up
- one-year
Methodological detailsmatched, TriNetX global research network, 147 healthcare organizations
- Matched
- TriNetX global research network
- 147 healthcare organizations
Main finding
Composite outcome
Hazard ratio
0.65
As reported in the abstract
Observational data: associations, not effects.
Further findings
Individual components (all-cause mortality, major adverse cardiovascular events (MACE), MAKE, MALO)
- SGLT2is associated with lower risks of all individual components
Subgroup and sensitivity analyses
- Subgroup and sensitivity analyses yielded consistent results
Original publication
Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM. Diabetes Res Clin Pract. Published 24 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →